By Ethan Huff
It has come to light that back in April, the U.S. Food and Drug Administration (FDA) sent a letter to a Google lobbyist demanding that a slew of videos on YouTube about the Wuhan coronavirus (Covid-19) be censored and removed because the federal agency did not approve of their content.
The FDA’s director of social media, Brad Kimberly, complained about “misinformation” in the videos that detracted from the White House’s position concerning the plandemic. One of the videos talked about a monoclonal antibody treatment, which some people are using as a treatment for Chinese Germs.
“Overall, the video is very problematic when it comes to COVID misinformation,” Kimberly wrote in the letter about the video promoting monoclonal antibodies. “This video should[emphasis added] be pulled.”
The recipient of this email was Google lobbyist Jan Fowler Antonaros, who apparently did not initially comply with the demand. However, the video in question was later removed by someone over at Google.
“How often the FDA has made other censorship demands is unknown, because the agency is apparently hiding the existence of its efforts in response to Freedom of Information Act requests,” warned Alex Berenson on his Substack about this issue.
Berenson himself asked the FDA and several other government agencies back in October to disclose both their internal discussions about him, as well as their communications with social media companies like Twitter and YouTube.
“On Nov. 30, the FDA responded it had found some emails about me – mainly in response to questions I had asked in April and May for a story about VAERS, the federal vaccine adverse events reporting system,” Berenson reported.
“But FDA said it could not find any emails between its officials and social media companies that met my request.”
Is the FDA actively threatening Big Tech to remove “offensive” content?
Interestingly, it was Berenson who appears to have accidentally received the email between Kimberly and Antonaros, which was mysteriously attached to the bottom of this email response from the FDA.
“… at the bottom of the emails containing the agency’s discussions about me was the email between Kimberly and Antonaros – apparently attached there by accident, as it had nothing to do with me,” Berenson explained.
The monoclonal antibody in question, known as leronlimab, had been under development by a small drug outfit called CytoDyn that currently trades at around $1 a share.
Provide, Protect and Profit from what’s coming! Get a free issue of Counter Markets today.